Given its success and tolerability in this pretreated population, brentuximab vedotin, an anti-CD30 antibody drug conjugate, was brought earlier in the disease course and is a model for advances in the targeted treatment of PTCL. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.